EDITORIAL SECTIONS

Ryan Varghese is a student and researcher affiliated with the Department of Pharmaceutical Chemistry, Poona College of Pharmacy, India. His work spans a spectrum of topics from artificial intelligence to cancer theranostics and drug delivery in Alzheimer's disease.His specialisation lies in the drug delivery modalities in chronic diseases. He has curated several articles on the lacunae in the Government public policies while providing solutions for the same. His recent works include the proposal of drug repurposing and affordable hospitalisation to mitigate the risk stemming from COVID-19 in India.

Sahil Salvi is a student and researcher associated with the Department of Pharmaceutical Chemistry, Poona College of Pharmacy, India. His works spans across a broad variety of topics, with specialisations in drug delivery and pharmaceutics, especially in chronic diseases. His keen interest in the latter has driven him to curate scientific articles in pharmaceutics and pharmacology.

Dileep Kumar is an assistant professor in the Department of Pharmaceutical Chemistry at Poona College of Pharmacy. He is a pioneer in his field with his forte in the treatment and novel drug delivery in Cancer and Alzheimer’s disease, especially adamantyl analogs as GluN2B selective NMDA receptor agonists. He is also an awardee of the Junior Research Fellowship from the National Medicinal Plant Board (NMPB) New Delhi, Senior Research Fellowship from the University Grants Commission (UGC), Teaching Assistantship, and Institute Post-Doctoral Fellowship from IIT (BHU) Varanasi. He is the Guest editor of Prestigious journals like Current Topics in Medicinal Chemistry, CTMC, Current drug target, combinatorial chemistry, and molecules.

Smita Agrawal holds a PhD in Chemical Engineering from the University of California, Berkeley. She has over 20 years of research experience in stem cell biology, neuroscience, immunology, genomics, oncology and real-world data. She currently serves as an independent consultant, offering strategic guidance and insights to life sciences companies on genomics, AI, and health care data applications.

Edwin Ng joined Medidata in 2014 and heads the Life Science industry of Dassault Systemes across the Asia Pacific region. Under his leadership, the company’s regional business recorded significant year-on-year growth and achieved multiple leadership awards. Edwin has spent the last 27 years of his career managing enterprise solutions businesses.

Dr. Asawari Pagare is a bioinformatician at UW Medicine where she studies the genomics of myositis, an autoimmune disease that is not yet well understood. She earned her PhD in Chemistry from the University of North Carolina at Chapel Hill, USA, where she explored how timing and fluctuations influence how living systems interpret signals relevant to medicine.

Associate Professor Dr. Oon Chern Ein is dedicated to advancing innovative cancer therapies. She earned her BSc (First Class Hons) in Biotechnology from Universiti Kebangsaan Malaysia and pursued her DPhil in Medical Oncology at the University of Oxford, United Kingdom. Following this, she trained as a postdoctoral fellow at Karolinska Institutet, Sweden. She has served as a lecturer at Universiti Sains Malaysia since 2013. Chern’s work in molecular therapeutics has earned her numerous prestigious awards, including the L’Oreal-UNESCO For Women in Science National Fellowship (2015), the Women of the Future Awards (South East Asia), and the Malaysian National Young Scientist Award (2018). She was further recognized with the Promising Academician Award and Excellent Service Award by the Malaysian Ministry of Higher Education (2019), alongside the British Council Study UK Alumni Award (Professional Achievement Category) and MINDS Women Scientist Award in 2020. Most recently, she received the Singapore Academies-ASEAN Fellowship from the Singapore National Research Foundation to train in drug discovery at A*STAR Singapore to strengthen her industrial insights. Her multidisciplinary research encompasses drug discovery, cancer-targeted therapies, and bioengineering solutions through collaborations with industry partners. She holds two granted patents in Malaysia (MY-203445-A, MY-199524-A) for small molecule inhibitors targeting anti-cancer and anti-angiogenesis pathways. As a member of the Global Young Academy, Chern actively champions female empowerment and education for all. Chern’s research continues to bridge academia and industry, striving to transform cancer therapy through novel therapeutic strategies.